Activity Overview
This online, on-demand virtual symposium brings together renowned experts in neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PNs). In this educational program, these experts use interactive case-based discussions and evidence-informed peer exchanges to address key decision points in diagnosis, targeted therapy selection, adverse event management, and longitudinal care coordination—with the goal of reducing practice variability and empowering community clinicians to deliver timely, personalized care for patients with NF1-PNs.
This educational activity is an archive of the live presentation held on August 12, 2026.
Target Audience
This educational program is primarily directed toward community-based oncologists, nurses, nurse practitioners/advanced practice providers, and other health care professionals involved in the treatment of patients with NF1-PNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize the diagnostic criteria and clinical presentation of plexiform neurofibromas in patients with NF1
- Review clinical trial data on MEK inhibitors for the treatment of NF1-associated plexiform neurofibromas
- Develop individualized management plans for patients with NF1-PN incorporating multidisciplinary care
- Identify strategies for monitoring and managing adverse events associated with MEK inhibitor therapy
Amy E. Armstrong, MD
Associate Professor of Pediatrics
Director, Solid Tumor Team
Codirector, Adolescent and Young Adult Sarcoma Program
Division of Pediatric Hematology/Oncology
Washington University in St Louis
St Louis, MO
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: SpringWorks; Speaker at Academic Conference: Alexion
Phioanh “Leia” Nghiemphu, MD
Professor, Department of Neurology, Neuro-Oncology Program
David Geffen School of Medicine at UCLA
Medical Director, UCLA Comprehensive NF and Schwannomatosis Clinic
Los Angeles, CA
Disclosures: Advisor/Consultant/Fee-for-Service: Alexion, Day One, Servier, SpringWorks; Speakers Bureau: Alexion, SpringWorks; Grant/Research Funding: Alexion, Erasca, Katmai, Millenium, Recursion, SpringWorks
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
